KLI

The safety and efficacy of CKD-497 in patients with acute upper respiratory tract infection and bronchitis symptoms: a multicenter, double-blind, double-dummy, randomized, controlled, phase II clinical trial

Metadata Downloads
Abstract
Background: Acute upper respiratory tract infection (AURI) together with acute bronchitis is the most common illness worldwide. Botanical medicines used as expectorants and antitussives have proven to be effective while also having excellent safety margins. We aimed at evaluating the efficacy and safety of a new botanical drug, CKD-497, in patients with AURI and acute bronchitis.
Methods: In this phase 2 study, 225 patients were enrolled and randomly assigned to one of four treatment groups: placebo (n=55), Synatura (R) (n=49), CKD-497 200 mg (n=68), or CKD-497 300 mg (n=53). The study drugs were administered three times daily over the course of 7 days. Primary endpoint was the change in the bronchitis severity score (BSS) from baseline to day 7. Secondary endpoint was evaluated based on clinical response rates on days 4 and 7. A safety analysis was also performed.
Results: Between baseline and day 7, the mean BSS scores decreased significantly in each group (P<0.001): -4.04 +/- 1.85, -4.31 +/- 1.47, -4.09 +/- 1.48, and -4.28 +/- 1.69. However, neither the CKD-497 nor Synatura (R) group showed any significant effect on the difference in BSS change (P=0.75). The rate of clinical response was higher in the CKD-497 300 mg group as compared to the placebo only on day 4 (36% vs. 18%; P<0.05) and those having more severe bronchitis (phlegm score >= 3) showed a significant reduction of total BSS in the Synatura (R) and CKD-497 groups (P=0.042). No significant adverse events were observed in either of the CKD-497 groups.
Conclusions: CKD-497 and even the positive control drug had no significant effect on BSS change in this phase 2 clinical trial. However, CKD-497 300 mg had a mild but significant clinical improvement in early bronchitis patients with more severe phlegm. Considering both efficacy and safety, a future study using 300 mg of CKD-497 with a shorter-term endpoint is warranted in patients with more severe bronchitis symptoms.
Author(s)
나승원김선영임윤영박신정이진국김덕겸박용범이창률윤형규박정웅유광하
Issued Date
2021
Type
Article
Keyword
Acute respiratory tract infectionbronchitisbronchitis severity score (BSS)CKD-497Original
DOI
10.21037/jtd-20-1567
URI
https://oak.ulsan.ac.kr/handle/2021.oak/7018
https://ulsan-primo.hosted.exlibrisgroup.com/primo-explore/fulldisplay?docid=TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7867795&amp;context=PC&amp;vid=ULSAN&amp;lang=ko_KR&amp;search_scope=default_scope&amp;adaptor=primo_central_multiple_fe&amp;tab=default_tab&amp;query=any,contains,The%20safety%20and%20efficacy%20of%20CKD-497%20in%20patients%20with%20acute%20upper%20respiratory%20tract%20infection%20and%20bronchitis%20symptoms:%20a%20multicenter,%20double-blind,%20double-dummy,%20randomized,%20controlled,%20phase%20II%20clinical%20trial&amp;offset=0&amp;pcAvailability=true
Publisher
JOURNAL OF THORACIC DISEASE
Location
중국
Language
영어
ISSN
2072-1439
Citation Volume
13
Citation Number
1
Citation Start Page
1
Citation End Page
9
Appears in Collections:
Medicine > Medicine
Authorize & License
  • Authorize공개
Files in This Item:
  • There are no files associated with this item.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.